200 Penobscot Drive
Redwood City, CA 94063
650 421 8100
Full Time Employees: 248
|Dr. Stephen George Dilly MBBS, Ph.D.||Pres, CEO & Director||753.61k||N/A||1960|
|Mr. Kevin Norrett M.B.A., M.S.||Chief Operating Officer||507.28k||N/A||1973|
|Ms. Margaret Fitzgerald J.D.||Chief Legal and Compliance Officer, Gen. Counsel & Sec.||300.03k||N/A||1971|
|Mr. John J. Nicols||Director & Strategic Advisor||1.29M||2.96M||1964|
|Mr. Sriram Ryali M.B.A.||Chief Financial Officer||N/A||N/A||1982|
|Ms. Karen Frechou-Armijo||Sr. VP & Head of HR||N/A||N/A||N/A|
|Mr. Rob Wilson Ph.D.||Sr. VP & GM of Performance Enzymes||N/A||N/A||N/A|
|Dr. Stefan Lutz Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
|Mr. Robert Sato M.B.A., Ph.D.||Sr. VP of Pharmaceutical Devel., Quality & Regulatory||N/A||N/A||N/A|
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis, Inc.’s ISS Governance QualityScore as of May 30, 2023 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 7; Compensation: 3.